Newron initiates U.S. Phase II trial in patients with schizophrenia

Newron Completes 5.4 Million USD/CHF Private Placement with U.S. Biotechnology/Healthcare Specialist Fund

Swissmedic approves Xadago® for use in Parkinson’s disease

Newron Pharmaceuticals Announces Planned Pivotal Trial Design for Sarizotan for Patients with Rett Syndrome, a Rare Neurodevelopmental Disease

Meiji announces Initiation of Phase II/III and Long-term Clinical Trials of ME2125 (safinamide) for the Treatment of PD

Xadago® (safinamide) New Drug Application - Late-Cycle Review Meeting Completed with U.S. FDA

Newron reports half-year 2015 results

Newron Receives FDA Orphan Drug Designation for Sarizotan for the Treatment of Rett Syndrome

Newron receives positive opinion for ODD for Sarizotan to treat patients with Rett Syndrome from EMA’s COMP

Zambon Launches Xadago® (Safinamide) For Patients With Mid- To Late-Stage Parkinson’s Disease In Germany

Pagination